G
Giuseppe Vita
Researcher at University of Messina
Publications - 298
Citations - 10861
Giuseppe Vita is an academic researcher from University of Messina. The author has contributed to research in topics: Transthyretin & Duchenne muscular dystrophy. The author has an hindex of 42, co-authored 285 publications receiving 8731 citations. Previous affiliations of Giuseppe Vita include Instituto Politécnico Nacional & Foundation University, Islamabad.
Papers
More filters
Journal ArticleDOI
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
David Adams,Alejandra González-Duarte,William O'Riordan,Chih-Chao Yang,Mitsuharu Ueda,Arnt V. Kristen,Ivailo Tournev,Hartmut Schmidt,Teresa Coelho,John L. Berk,Kon Ping Lin,Giuseppe Vita,Shahram Attarian,Violaine Planté-Bordeneuve,Michelle M. Mezei,Josep M. Campistol,Juan Buades,Thomas H. Brannagan,Byoung Joon Kim,Jeeyoung Oh,Yesim Parman,Yoshiki Sekijima,Philip N. Hawkins,Scott D. Solomon,Michael Polydefkis,Peter J. Dyck,Pritesh Gandhi,Sunita Goyal,Jihong Chen,Andrew Strahs,Saraswathy V. Nochur,Marianne T. Sweetser,Pushkal Garg,Pushkal Garg,Akshay Vaishnaw,Akshay Vaishnaw,Jared Gollob,Ole B. Suhr +37 more
TL;DR: Patisiran improved multiple clinical manifestations of hereditary transthyretin amyloidosis with polyneuropathy and showed an effect on gait speed and modified BMI.
Journal ArticleDOI
Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis
Merrill D. Benson,Márcia Waddington-Cruz,John L. Berk,Michael Polydefkis,Peter J. Dyck,Annabel K. Wang,Violaine Planté-Bordeneuve,Fabio Barroso,Giampaolo Merlini,Laura Obici,Morton A. Scheinberg,Thomas H. Brannagan,William J. Litchy,Carol J. Whelan,Brian M. Drachman,David C. Adams,Stephen B. Heitner,Isabel Conceição,Hartmut H. Schmidt,Giuseppe Vita,Josep M. Campistol,Josep Gamez,Peter D. Gorevic,Edward Gane,Amil M. Shah,Scott D. Solomon,Brett P. Monia,Steven G. Hughes,Jesse Kwoh,Bradley W. McEvoy,Shiangtung W. Jung,Brenda F. Baker,Elizabeth J. Ackermann,Morie A. Gertz,Teresa Coelho +34 more
TL;DR: Inotersen improved the course of neurologic disease and quality of life in patients with hereditary transthyretin amyloidosis and improvements were independent of disease stage, mutation type, or the presence of cardiomyopathy.
Journal ArticleDOI
Ataluren in patients with nonsense mutation Duchenne muscular dystrophy (ACT DMD): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
Craig M. McDonald,Craig Campbell,Ricardo Erazo Torricelli,Richard S. Finkel,Richard S. Finkel,Kevin M. Flanigan,Nathalie Goemans,Peter Heydemann,Anna Kamińska,Janbernd Kirschner,Francesco Muntoni,Andrés Nascimento Osorio,Ulrike Schara,Thomas Sejersen,Perry B. Shieh,H. Lee Sweeney,Haluk Topaloglu,Mar Tulinius,Juan J. Vílchez,Thomas Voit,Thomas Voit,Brenda Wong,Gary Elfring,H. Kroger,Xiaohui Luo,Joseph McIntosh,Tuyen Ong,Peter Riebling,Marcio Souza,R. Spiegel,Stuart W. Peltz,Eugenio Mercuri,Lindsay N. Alfano,Michelle Eagle,M. James,Linda Lowes,Anna Mayhew,Elena S. Mazzone,Leslie Nelson,Kristy Rose,Hoda Abdel-Hamid,Susan D. Apkon,Richard J. Barohn,Enrico Bertini,Clemens Bloetzer,Lausanne Canton de Vaud,Russell J. Butterfield,Brigitte Chabrol,Jong-Hee Chae,Daehak-ro Jongno-gu,Giacomi Pietro Comi,Basil T. Darras,Jahannaz Dastgir,Isabelle Desguerre,Raul G Escobar,Erika Finanger,Michela Guglieri,Imelda Hughes,Susan T. Iannaccone,Kristi J. Jones,Peter I. Karachunski,Martin Kudr,Timothy Lotze,Jean K. Mah,Katherine D. Mathews,Yoram Nevo,Julie A. Parsons,Yann Péréon,Alexandra Prufer de Queiroz Campos Araujo,J. Ben Renfroe,Maria Bernadete Dutra de Resende,Monique M. Ryan,Kathryn Selby,Gihan Tennekoon,Giuseppe Vita +74 more
TL;DR: Ataluren was generally well tolerated and most treatment-emergent adverse events were mild to moderate in severity, and there was a significant effect of ataluren in the prespecified subgroup of patients in the intention-to-treat population.
Journal ArticleDOI
miR-21 and 221 upregulation and miR-181b downregulation in human grade II–IV astrocytic tumors
Alfredo Conti,M'hammed Aguennouz,Domenico La Torre,Chiara Tomasello,Salvatore Cardali,Filippo Flavio Angileri,Francesca Maio,Annamaria Cama,Antonino Germanò,Giuseppe Vita,Francesco Tomasello +10 more
TL;DR: The different expression pattern observed in tumors at different stages of malignancy is probably dependent on the cell-specific repertoire of target genes of tumors sharing different molecular pathways activity and suggests miRNAs may have also a place in diagnosis and staging of brain tumors.
Journal ArticleDOI
Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial
Davide Pareyson,Mary M. Reilly,Angelo Schenone,Gian Maria Fabrizi,Tiziana Cavallaro,Lucio Santoro,Giuseppe Vita,Aldo Quattrone,Aldo Quattrone,Luca Padua,Franco Gemignani,Francesco Visioli,Francesco Visioli,Matilde Laura,Davide Radice,Daniela Calabrese,Richard A. C. Hughes,Alessandra Solari +17 more
TL;DR: Ascorbic acid supplementation had no significant effect on neuropathy compared with placebo after 2 years, suggesting that no evidence is available to support treatment with ascorbIC acid in adults with CMT1A.